EDOFLO Powder for Inhalation 100/6 Mcg/Dose

Country: Ireland

Language: English

Source: HPRA (Health Products Regulatory Authority)

Buy It Now

Active ingredient:

BUDESONIDE FORMOTEROL FUMATRATE DIHYDRATE

Available from:

AstraZeneca UK Limited

Dosage:

100/6 Mcg/Dose

Pharmaceutical form:

Powder for Inhalation

Authorization date:

2010-11-26

Summary of Product characteristics

                                SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Edoflo 100micrograms/6micrograms/Inhalation, Inhalation powder
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each delivered dose (the dose that leaves the mouthpiece) contains: budesonide 80 micrograms/inhalation and
formoterol fumarate dihydrate 4.5 micrograms/inhalation.
Each
metered
dose
contains:
budesonide
100 micrograms/inhalation
and
formoterol
fumarate
dihydrate
6 micrograms/inhalation.
Excipient: Lactose monohydrate 810 micrograms per dose.
For a full list of excipients, see section 6.1
3 PHARMACEUTICAL FORM
Inhalation powder.
White powder.
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
Edoflo is indicated in the regular treatment of asthma where use of a combination (inhaled corticosteroid and
long
-acting
2
adrenoceptor agonist) is appropriate:
-
patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short
-acting
2
adrenoceptor agonists.
or
-
patients already adequately controlled on both inhaled corticosteroids and long
-acting
2
adrenoceptor agonists.
NOTE: Edoflo (100 micrograms/6 micrograms/inhalation) is not appropriate in patients with severe asthma.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
Route of administration: For inhalation use
Edoflo is not intended for the initial management of asthma.
The dosage of the components of Edoflo is individual and should be adjusted to the severity of the disease. This should
be considered not only when treatment with combination products is initiated but also when the maintenance dose is
adjusted. If an individual patient should require a combination of doses other than those available in the combination
inhaler , appropriate doses of
2
adrenoceptor agonists and/or corticosteroids by individual inhalers should be
prescribed.
The dose should be titrated to the
                                
                                Read the complete document